preparation procedure fixes and or assigns any missing bonds, bond order, charges, and 157 protonation states in order to make proper predictions during docking. Prior to docking ,an ATP 158 binding domain pocket with a volume of 338 Å 3 was identified in our ROP18 II homology model 159 using MVD's built-in cavity detection algorithm (48) . For the docking simulation we employed 160 the MolDock scoring function in combination with the MolDock SE search algorithm and Tabu 161 clustering (11). A search space volume of radius 15Å encompassing the ATP binding domain 162 was chosen for docking, and both the ligands and catalytic pocket residues were allowed to be 163 flexible during the simulation. Each ligand was docked iteratively into the chosen cavity in ten 164 independent runs, each of which consisted of 1500 steps. Poses generated from each run were 165 subjected to Tabu clustering whereby the lowest energy pose below an energy score (Moldock 166 E.Score; (46) ) of 100 was generated as output. Thus, there were 10 poses per ligand ranked by 167 energy. The lowest energy pose of the 10 poses per ligand was selected for visual inspection by 168 comparing the orientation of the molecule to a reference ATP pose docked in a similar fashion. 169
The reference ATP pose (shown in Fig. 1 ) had the lowest free energy and similar orientation to 170 bound ATP in mouse PKA (Protein Kinase A, PDBID: 1ATP (55)). Ligands that had similar 171 docking orientations as the reference ATP pose were chosen for in vitro growth screens. 172
173

Passage of Human Fibroblast Cell Line 174
Human foreskin fibroblasts (HFFs) were passed and maintained at 37 o C and 5% CO 2 in 175 Dulbecco's Modified Eagle Medium with 10% fetal calf serum, 2 mM glutamine, and 50 ug/mL 176 each of penicillin and streptomycin (cDMEM) . 177
178
Parasite strains 179
In most of the in vitro assays we used strain 5A10, which was constructed as follows: 180 strain CEP∆HXGPRT (a type III strain) was transfected with a construct containing both GFP 181 and click beetle luciferase (under control of the GRA2 and DHFR promoters, respectively), 182 sorted using flow cytometry, and GFP positive clones were isolated using limiting dilution. To 183 complement the HXGPRT defect of this strain, it was then transfected with the vector pGRA-184 HA-HXGPRT (44), selected for the presence of the plasmid using selection with mycophenolic 185 acid and xanthine (MPA/X) as described previously (22), and cloned by limiting dilution. Strain 186 PB3-10 was derived from strain ME49B7 by transfecting with the same click beetle 187 luciferase/GFP plasmid as 5A10, sorted using flow cytometry, and cloned by limiting dilution. 188
To test the effects of ROP18 II expression on compound sensitivity, strain CEP∆HXGPRT was 189 transfected with an HA-tagged version of the type II allele of ROP18 (including 538 bp of 190 upstream promoter sequence (44)) and cloned by limiting dilution after MPA/X selection. When 191 this strain was used to infect mice it showed the same increase in virulence associated with 192 expression of type II ROP18 in a type III strain as described previously (i.e., injection with 1,000 193 parasites was uniformly lethal; (44)). 
Extracellular and intracellular parasite treatments 213
To test the effects of compound treatment on extracellular parasites and HFF monolayers, 214 freshly lysed parasites and confluent monolayers were treated separately for 16 h with either 215 vehicle or 2µM F1792-0016, and then washed 3X with 200 µL cDMEM. Then, treated parasites 216 were used to infect untreated monolayers while freshly lysed parasites were used to infect treated 217 monolayers for 3 days prior to harvest and luminescence assays. To test the effects of compound 218 exposure on intracellular parasites, HFFs in 96 well plates were infected for 4 h and then treated 219 for 24 h with either 2 µM F1792-0016 or vehicle. After washing with cDMEM, wells were then 220 treated with vehicle or compound. In this assay we tested 3 conditions: 1) 24 hours vehicle 221 followed by 48h vehicle (control); 2) 24h compound treatment followed by 48 h vehicle; 3) 24 222 hours compound followed by 48h compound. Plates were harvested and analyzed for 223 luminescence as described above. to formazan, which absorbs at 490 nm. HFF's were seeded into 96-well plates (BD Falcon, NJ) 232 and incubated for 72 hrs. Media was removed and the cells were treated with each compound at a 233 final concentration 10 µM in phenol-red free cDMEM for 72 hr. Staurosporine (10 µM) and 234 vehicle were included as a positive and negative control respectively. Three independent 235 experiments were done for each compound in replicates of ten per experiment. Absorbance at 236 490 nm was recorded using an iMark™ Microplate Absorbance Reader (Bio Rad, Hercules, CA). 237
238
Fluorescence and Electron Microscopy 239
Confluent HFF monolayers on coverslips were infected with 20,000 parasites/well for 4 240 hours, washed, and then treated with 2 µM and 0.01 µM F1792-0016 or vehicle. Cells were 241 fixed with 4% formaldehyde and processed for fluorescence microscopy on days 1, 2, 3, and 4 242 post-treatment. Slides were examined using a Zeiss Axiophot upright microscope equipped with 243 a 100X Oil immersion objective. The F1656-0035 phenotyping was performed using confluent 244
T25s infected with 100,000 parasites per flask and treated with 10 µM F1656-0035. The T25s 245 were visualized using Zeiss Axiovert microscope equipped with a 40X objective on each day. 246
For electron microscopy, confluent HFF monolayers in 6 well plates were infected with 247 parasites at an MOI of 1 for 4 hours, washed, and then treated with 2µM compound or vehicle. 248
After 56 hours exposure, the monolayers were washed briefly in PBS (pH 7.4) and fixed with 2.5 249 % glutaraldehyde in PBS for 12 hours at room temperature. The monolayers were then washed 3 250 times in PBS and post-fixed in 1% osmium tetroxide in 1% potassium ferricyanide for 1hr at 4º 251 C. Monolayers were washed 3 times in PBS and then dehydrated in a graded ethanol series (30, 252 50, 70, and 90%) . The final dehydration step was done 3 times in 100% ethanol with 15 minute 253 incubations between changes. Upon dehydration, the monolayers were then incubated for three 254 hours in epon which was changed every hour. After the final epon incubation, beem capsules 255 were inserted into the monolayer and allowed to polymerize overnight at 37º C and then for 48 256 hours at 60º C. Sections were visualized using JEM-1011 Transmission electron microscope 257 (JEOL Ltd, Tokyo, Japan). 258
259
Microarray analyses 260
Parasites growing in confluent HFF monolayers were syringe released and quantified as 261 described above. Resuspended parasites were then centrifuged at 800 x g and washed 2X with 262 10 mL cDMEM. Washed parasites were resuspended in enough fresh media to infect HFF's in 263 T25's at a multiplicity of infection (MOI) of 1.5. The parasites were allowed to grow overnight, 264 and divided into 3 different treatment groups: Group 1 had media replaced with 2 µM F1792-265 0016, group 2 with 10 µM F1792-0007, and group 3 with vehicle. In parallel, uninfected HFF's 266 were divided into 3 sets of three and treated similarly. Both infected and uninfected flasks were 267 incubated for 24 and 48 h, and RNA extraction and labeling was performed per the manufacturer 268 recommendations using TRIzol Reagent (Invitrogen, Carlsbad, CA) For the human WG-6 illumina bead chips, data were normalized using the cubic spline 277 method in BeadStudio v3 (23), while the data from the Toxoplasma affymetrix chip was 278 normalized using the Affy package implemented in R using the quantile normalization method 279 and log 2 transformed using median polishing (26). To identify genes with significantly different 280 abundance between treatment groups for both sets of microarrays, we used the Linear Models for 281
Microarray Analysis package as implemented in R (R/Limma; (46)). After linear model fitting, 282 raw P-values were calculated for each gene for contrasts of vehicle versus F1792-0016 treatment 283 and vehicle versus F1792-0007 treatment for the 48 h timepoint. To control for the testing of 284 multiple hypotheses, the False Discovery Rate method was used to adjust P-values. Genes were 285 deemed to be of significant differential abundance if the adjusted P-value was less than 0.05 and 286 the absolute value of the fold-difference was ≥2. 287
Gene ontology analyses of Toxoplasma transcripts were carried out using GeneMerge 288 (14), and utilized the most recently released version of the annotated Toxoplasma gondii genome, 289 for which there is at least one GO annotation for 3,202 genes (www.toxodb.org). This software 290 uses the hypergeometric distribution to determine if particular GO categories are enriched in 291 groups of differentially expressed genes when compared to all of the genes on the microarray 292 (14). In addition, it uses a highly stringent Bonferroni P-value correction (based on the total 293 number of GO categories represented on the microarray) to adjust P-values and control the 294 experiment-wise error rate (14). In separate analyes, the GO annotations for all genes on the 295 array that were either of significantly higher or lower abundance after 48 h treatment with 296 F1792-0016 (identified as described in the preceding paragraph) were loaded as the "study" 297 group, and all of the GO-annotations were loaded as the "population group". GO categories 298
were deemed significantly enriched in the higher or lower abundance gene sets if they had 299 adjusted P-values < 0.05. 300
Statistical Analyses of Compound treatment data 301
Raw luminescence data for all runs were log 2 transformed, and significant differences 302 between vehicle and compound treatment were identified by one-way ANOVA followed by a 303
Bonferroni-Holm post-hoc test. Bonferroni corrections were always based on the number of pre-304 determined comparisons (in most cases, vehicle versus all compound treatments). Treatments 305 were considered significant at P<0.05. 306
Flow cytometric analyses of cell cycle 307
Parasites were used to infect monolayers for 24 h and then treated as above with either 308 vehicle or 2 µM F1792-0016 for 24 and 48 h, and then harvested for cell cycle analyses as 309 described previously (36). Briefly, intracellular parasites were isolated by passage of host cells 310 through a 30-gauge needle followed by filtration through a 3.0µm pore-size membrane 311 (Whatman). Parasites were then fixed in 70% ethanol and their DNA stained using 1 µm Sytox 312 Green (Invitrogen, Carlsbad, CA) plus 50 units RNase A, 200 units RNase T1 (Ambion, Foster 313 City, CA) per ml, in 50mM Tris, pH 7.5. Samples were analyzed on a FACSAria flow cytometer 314 (BD Biosciences, Franklin Lakes, NJ). Results were analyzed using FlowJo software (Tree Star), 315 and the percentage of parasites in each phase of the cell cycle (G1 or S/M) was determined by 316 gating. All assays were performed in triplicate and percentages of parasites in the S/M phase of 317 the cell cycle were compared for statistical significance between control and test groups by use 318 of a two-tailed t test (P < 0.05) using JMP software (SAS Institute, Cary, NC). At least 10,000 319 events were collected per sample. 320
321
RESULTS: 322
Sequence alignment and model building 323
Since the percentage identity of ROP18 II to the two best available templates (ROP2 and 324 ROP8) falls below 30%, we manually aligned the target sequence with the templates as 325 described in the Materials and Methods section. Ramachandran plot analysis showed that 90% 326 of the residues were in the "most favored" region, 9.4% in the "allowed region" and 0.7% were 327 in the "disallowed" region, and the RMSD between the templates and the model was 0.66Å and 328 0.37 Å with ROP2 and ROP8 respectively. The overall topology of the modeled Type II ROP18 329 consists of 13 beta strands and 15 alpha helices, encompassing residues 224-536 (Figs 1 and 2). 330
To validate our model we compared our modeled ATP binding site to a recently published 331 homology model of another ROP18 allele (that from the type I strain; RH) that was also based on 332 the ROP2 and ROP8 structures (3dzo and 3byv, respectively; (41) 
Similarity searches, toxicity predictions and virtual docking 356
Recognition of small molecules by proteins is largely mediated by molecular surface 357 complementarities. Structure-based drug design approaches use this as the fundamental guiding 358 principle; that is, closely related molecules will elicit similar activity in a biological assay (38, 359 54), and we searched our selected libraries for compounds with the highest similarity to ATP. 360
Three hundred and five compounds from the Life Chemical Library and 336 compounds from 361 the ZINC 8.0 drug-like dataset showed a similarity to ATP higher than 70%, and were subjected 362 to further analyses. To these molecules we applied in silico assessment of ADME/Tox 363 properties using ACD ADME/TOX software (1). Based on this screen we selected 199 364 compounds from the Life Chemicals library and 100 molecules from the ZINC8.0 drug-like 365 dataset with the best ADME/Tox properties. These 299 compounds were docked using Molegro 366
Virtual Docker (MVD) software (48). A total of 17 molecules were selected based on both the 367 MolDock energy score (48) and the way they fit into the ATP binding site (Fig. 3) . 368 369
F1792-0016 inhibits Toxoplasma growth in vitro 370
We hypothesized that small molecules designed to fit into the ATP binding pocket of 371 ROP18 may make excellent candidate compounds with the capacity to interact with members of 372 this superfamily. By testing only a small number of compounds (i.e., 17) we identified one 373 compound that significantly affected the growth of strain 5A10 (a type III strain) in vitro (Fig. 4) . 374
This compound, F1792-0016 (see Fig. 3 for structures) was the most potent, decreasing parasite 375 growth by 96±0.14% (P<0.001 compared to vehicle control). Dose curves showed that IC50 of 376 F1792-0016 is 2.1 ± 1.8 nM (Fig. 5A ), but there is also a reproducible plateau between 10 and 377 100 nM, suggesting that this compound may have multiple binding sites and/or targets with 378 different inhibitory concentrations. In that 5A10 is a type III strain, and is known to express very 379 low levels of ROP18 (44), we also determined the IC50 of F1792-0016 against a type III strain 380 engineered to express a type II allele of ROP18, and found it to be similarly sensitive to the 381 compound as 5A10 (IC50=3.6 ± 2.3 nM). This suggests that while we chose this compound 382 based on the potential to inhibit ROP18, it is unlikely that the mechanism of killing is due to 383 direct interaction with this kinase. 384 While F1792-0016 was soluble in liquid media at all tested concentrations, it crystallized 385 only after it was placed in the presence of host cells at 10 µM. F0920-5744 also inhibited 386 parasite growth by 40.60 ± 4.73%, but the host cells were also rounded and distorted, suggesting 387 that this compound may be toxic to host cells. Therefore, for this study we focused on further 388 characterizing the effects of F1792-0016 on parasite growth. 389
Two other compounds showed moderate enhancing effects in our primary screen of our 390 17 compound set (ST055366 and ST4033541; 190 and 145 % of control, respectively; Fig. 4) , 391 although these increases were not found to be statistically significant (P>0.05). We conducted 392 further experiments with ST055366 and found that it consistently enhanced parasite growth in a 393 type III strain (clone 5A10; 220% of control) and equally well in a type III strain engineered to 394 express high levels of ROP18 II (223% of control), indicating that this enhancing effect is 395 unlikely due to interactions with ROP18 II . Compound ST4033541 did not show any significant 396 enhancement of growth in subsequent assays (data not shown). 397
398
A Screen of Second Generation Compounds Shows a Potential Relationship between Structure 399
and Function 400
To identify analogs of F1792-0016 we used it as a scaffold in similarity searches using 401 PubChem (pubchem.ncbi.nlm.nih.gov) and identified 3 other compounds with similarity to 402 F1792-0016 of at least 0.9 (based on Tanimoto scores; (28); Fig. 3 ). One compound, F1656-403 0035, showed mild inhibition of parasite growth (62.90±9.44%, P< 0.01) and is structurally 404 identical to F1792-0016 except for an additional methyl group. This modification increased the 405 solubility of the compound, in that concentrations as high at 30 µM were soluble in DMSO 406 (compared to 2 µM for F1792-0016). In contrast, two compounds (F1792-0007 and F1792-0008) 407 consistently increased parasite growth after 3 days of treatment (250±49.0% and 223±23.5% 408 respectively; P<0.0001 for both) and are structurally similar to F1792-0016 except for the bond 409 between the two oxygens on the benzodioxole moiety has been broken. F1792-0007 and F1792-410 0008 have EC50s of 0.04 ± 0.02 µM and 0.1 ± 0.07µM, respectively (Fig. 6) . 411
412
Active compounds do not show evidence for toxicity to human fibroblast host cells 413
Using a tetrazolium reduction assay (MTS; (16) whether the inhibitory effects of the compound were reversible, we treated intracellular parasites 428 for 24 h with either vehicle or 2 µM F1792-0016, thoroughly washed the monolayers to remove 429 the compound, and allowed them to grow for another 48 h in the presence of either vehicle or 2 430 µM F1792-0016. Interestingly, growth compared to controls after 24 h treatment and washing 431 (14.6 ± 4.2 % of control) was very similar, and not significantly different (P=0.48), from that 432 observed by growing the parasites in the presence of the compound for the full 3 day period 433 (10.6 ± 2.2% of control; Fig. 5D ). Overall these data suggest that while the effects of the 434 compound on total parasite numbers (as measured by luminescent signal from the parasites) are 435 not observed until 3 days after drug exposure (Fig. 5B) , the binding of the compound to its 436 target(s) may be irreversible, or exposure to the compound for 24 h initiates a cascade that 437 eventually lead to parasite growth inhibition and/or death. Despite the irreversible effect of the 438 compound on intracellular parasites after only 24 h exposure, the compound showed only mild 439 effects that were not statistically significant (P=0.56; 62 ± 7.0% of control; Fig. 5D ) on parasites 440 pretreated for 16 h and washed prior to invasion and 3 days of growth (Fig 5D) . Similarly, only 441 mild inhibitory effects (P=0.60; 85 ± 17% of control) were observed when parasites were 442 allowed to invade pretreated and washed host cells, showing that compound disruption of key 443 host cellular processes is not responsible for reduced parasite growth. 444
445
F1792-0016 destroys parasite-containing vacuoles 446
To visualize the effects of F1792-0016 on parasite morphology, we treated GFP-447 expressing parasites with either vehicle or 2 µM F1792-0016, and examined them after 24, 48 448 and 72 h of treatment using fluorescence microscopy, and after 56 h of treatment using electron 449 microscopy. We observed that a characteristic of F1792-0016 treatment is the appearance of 450 vacuoles that fluoresce in the GFP channel, but do not contain any individually defined parasites 451 (Fig. 7) . We quantified the percentage of vacuoles with this phenotype over time, and found that 452 their numbers increase linearly over the span of 3 days, from 7.2 ± 3.5% on day 1 to 63.0 ± 8.0% 453 on day 3 (P<0.001; Fig. 5C ). In contrast, on days 1, 2 and 3 a very low percentage (<1% for all 454 time points) of these destroyed vacuoles are seen in the cDMEM/1% DMSO-exposed controls 455 (Fig. 5C ). This phenotype is less evident in parasites treated with 0.01 µM F1792-0016, in that 456 after 2, 3 or 4 days of treatment with 0.01 µM F1792-0016, only 9, 18, and 21% of vacuoles 457 were found to be lysed, respectively. A known lethal inhibitor of Toxoplasma gondii, FUDR, 458 also produces this same lysed phenotype (Meehan and Boyle, unpublished data), suggesting that 459 2 µM F1792-0016 is killing T. gondii which then results in destruction by the host cell. Since 2 460 µM F1792-0016 appears to kill the parasites, this explains why the effect is irreversible after 24 461 hours (Fig. 5D) , and suggests that F1792-0016 has an early effect on T. gondii that is not 462 observed until 72-96 h post-treatment. In addition, while F1792-0016-treated vacuoles appear to 463 be disrupted by both phase contrast and GFP fluorescence, DNA staining with Hoechst dye 464 reveals that the parasite nuclei are still capable of binding DNA dyes (Fig. 7) . Treatment with 10 465 µM F1656-0035 (the F1792-0016 analog) also resulted in a gradual increase in the same 466 phenotype as observed with F1792-0016 treatment (Meehan and Boyle, unpublished data). 467
Visualizing the parasite ultrastructure after 56 h treatment with vehicle or 2µM F1792-468 0016 using electron microscopy provides a clearer picture of parasite fate. Treated parasites 469 have an intact parasitophorous vacuole membrane (PVM) and nuclei, but individual parasites are 470 enlarged with a rounded feature that lacks a defined anterior or posterior position as compared to 471 vehicle controls (Fig 7G,H) . Most of the parasites organelles are either missing or deformed 472 while some of the parasite's plasma membrane is broken leading to organelle leakage into the 473 parasitophorous vacuole (PV). The PV is also very dense compared to controls. The compound 474 mode of killing seems to involve the destruction of parasite membrane integrity which leads to 475 the lysis of the parasites. F1792-0016 and F1656-0007. 493 While the data summarized above suggest that F1792-0016 and F1656-0007 act directly 494 on parasites, it is possible that these compounds may affect parasite growth and/or viability by 495 altering the host cell environment. As a first step to examine the effects of these compounds on 496 host cells, uninfected fibroblast monolayers were treated for 48h with compound or vehicle and 497 RNA was harvested for microarray analyses. Transcript abundance was determined using 498 Illumina WG-6 human gene chips. Out of the 37,805 host genes queried on the chip, only 3 499 were found to be of different abundance in F1792-0016-treated cells when compared to controls 500 (at least 2-fold different between treatments, and an adjusted P-value<0.05; see Materials and 501 Methods). The gene with the largest difference was cytochrome P450, which was 3.4-fold lower 502 in F1792-0016 treated cells (adjusted P=3x10 -6 ). Interestingly, all 3 genes with different 503 abundance in F1792-0016-treated cells were also significantly different in F1656-0007 treated 504 cells, suggesting that some of these genes may be characteristic responses of human cells for 505 processing chemical insults. Again, cytochrome P450 was the gene with the greatest abundance 506 difference in the presence of F1656-0007 (4.0-fold lower abundance; adjusted P=1x10 -6 ). The 507 second most altered transcript in both compound treatments was that coding for TCDD-inducible 508 poly(ADP-ribose) polymerase (TIPARP), which was 2.1-fold lower in treated cells (P<4x10-5 509 for both compounds). TIPARP is involved in cellular responses to exposure to dioxin (12), 510 although it is typically upregulated by toxin exposure rather than being downregulated as we saw 511 in our experiments (21). Overall, the effects of these compounds on uninfected human 512
Microarray analyses of host cells treated with
fibroblasts in vitro appears to be subtle, and the changes that do occur are in a small number of 513 genes involved in dealing with chemical-induced stress. 514 515 F1792-0016 and F1656-0007. 516 In contrast to the paucity of changes in host cell transcript levels due to compound 517 exposure, parasite transcripts were dramatically altered due to treatment with F1792-0016. In all 518
Microarray analyses of parasites treated with
629 Toxoplasma genes (out of 8059 queried on the chip) were found to be of different abundance 519 after 48 h of F1792-0016 treatment. In a separate experiment, we also examined transcript 520 abundance 24 h post-compound exposure and compared it to that observed at the 48 h timepoint. 521
Of the 629 T. gondii genes that were found to be of different abundance at the 48 h timepoint, 522 142 of these (~22%) were at least 2-fold different compared to the 24 h vehicle control (Fig. 8) . 523
While statistics were not possible on the 24 h data since we only had one biological replicate, 524 they suggest that some of the effects on parasite transcription are evident as early as 24 h after 525 compound exposure. However, clearly the most potent effects on transcription occur at the 48 h 526 timepoint (Fig. 8) . 527 This is not surprising, given the extreme phenotypic effects observed and that at this 528 timepoint ~30% of the vacuoles have been destroyed (see Figs. 5 and 7) . Gene Ontology 529 analyses on those genes of higher and lower abundance in the presence of F1792-0016 for 48 h 530 revealed a number of GO categories that were significantly enriched in each of these gene 531 populations (Table 1) . Specifically, genes that were of higher abundance in F1792-0016-treated 532 parasites were enriched for the GO annotations for nucleosome and nucleosome assembly 533 (P=2x10 -5 and 1.3x10 -4 , respectively) including Histone H2A and its paralogs. Genes that were 534 of lower abundance in the presence of F1792-0016 were significantly enriched for a number of 535 GO categories, including the proteasome (prosome; P=4.3x10 -6 ) and other genes involved in 536 intracellular protein transport and degradation (see Table 1 and Fig. 8 ). In addition, of the 27 537 genes of at least 3-fold lower abundance in F1792-0016-treated parasites, 11 of them are genes 538 that are either annotated as specific to cyst stages of the parasite (bradyzoites) or that have a clear 539 pattern of upregulation in bradyzoites based on publicly available data (www.toxodb.org). In the 540 present study many of these bradyzoite specific genes were found to be of relatively high 541 abundance in parasites treated with vehicle alone, and based on unpublished data from our 542 laboratory as well as others (www.toxodb.org) with the same strain (ME49), these levels are 543 much higher than is typical for tachyzoites in culture. This could be due to stresses that are 544 placed on the parasite by the presence of 1% DMSO (although we have found that this treatment 545 does not significantly alter the growth of parasites in vitro), and regardless of the reasons for 546 atypically high levels of these bradyzoite-specific genes, it is clear from our data that parasites 547 treated with F1792-0016 have significantly lower levels of these transcripts than controls. This 548 suggests that the compound may be either downregulating the expression of key stress-related 549 genes in the parasite, and/or the parasite may be locked in a phase of the cell cycle during which 550 these genes tend to be expressed at lower levels (8). 551
An advantage of the Toxoplasma microarrays used in this study (available through 552 www.upenn.edu; (3)) is that they also have probes for 297 human genes that are detectable when 553 hybridizing labeled RNA from Toxoplasma-infected host cells prepared as we have for this study. 554 Interestingly, while as described above very few genes (11 in all) were of different abundance in 555 host cells treated with F1792-0016 in the absence of Toxoplasma, 182 of the 297 human host 556 genes on the Toxoplasma expression chip were of different abundance in infected cells treated 557 with F1792-0016 (Fig. S1 ). Of these, the vast majority (179/182) were of higher abundance in 558 the presence of F1792-0016. The most dramatically upregulated genes were stromal-cell derived 559 factor 1 (SDF1; 12.0-fold higher; P=2.3x10 -4 ), LIM-domain binding protein 2 (LDB2; 11.0-fold 560 higher; P=2.5x10 -4 ), and small-inducible cytokine subfamily B, member 10 (SCYB10; 9.0-fold 561 higher; P=0.002). Importantly, none of these genes were altered by F1792-0016 treatment in 562 cells that were NOT infected (all data are available through the Geo Repository). Other host cell 563 transcripts of higher abundance in F1792-0016-treated, Toxoplasma-infected cells include TLR4, 564 IL10 receptor beta, and STAT2. A subset of these data can be found in figure S1 . 565
Overall, our microarray analyses found that 1) host cells treated with these active 566 compounds alone appear to be only moderately affected in terms of their transcriptional profile, 567
and 2) that treatment of Toxoplasma with F1792-0016 leads to rampant changes in gene 568 transcription in both Toxoplasma genes as well as a subset of host cell genes, and that this may 569 reflect alterations or blocks in the cell cycle. 570 571
F1792-0016 treatment alters the cell cycle of T. gondii. 572
Given the significant enrichment for nucleosome-related genes in F1792-0016-treated 573 parasites, we wanted to determine if progression through the cell cycle was blocked or altered by 574 compound treatment. When parasites were treated for 48 h with 2 µM F1792-0016, 51 ± 1.0% 575 of the parasites were in the S/M phase of the cell cycle compared to 32 ± 2.4% in untreated 576 controls (P=0.0002; Fig. 9 ). This suggests a possible mechanism of action for F1792-0016 may 577 be to arrest parasites in the S/M phase of the cell cycle, as has been seen with other inhibitors of 578
T. gondii growth such as monensin (36). Previously mutants resistant to the antibiotic monensin 579
were identified and we also examined whether one such mutant (MSH-1) was also resistant to 580 F1792-0016, and found that it was equally susceptible to F1792-0016 as a wild-type strain (for 581 both strains 48 h F1792-0016 exposure resulted in 40% S/M parasites compared to 29% in 582 controls; P>0.05). 583
584
DISCUSSION 585
In this study we used chemoinformatics approaches to identify compounds that may have 586 affinities for protein kinases and/or other ATP-binding proteins in the human pathogen 587
Toxoplasma gondii, and tested in vitro the effects of these compounds on parasite growth. 588
Members of the ROP2 superfamily of secreted protein kinases are known to play key roles in 589 parasite pathogenesis (10), including the secreted kinase ROP18, which has moderate effects on 590 parasite growth in vitro (25) and potent effects on pathogenesis in the mouse (44). To do this we 591 generated a homology model of type II ROP18 based on the most closely-related homologues 592 with solved structures, and used virtual docking to identify compounds that docked with 593 comparatively low energy into the ATP binding site of the homology model. Simultaneously, 594
we performed morphological similarity searches using two different commercially available 595 libraries to identify compounds that are highly similar to the ATP. In principle we aimed to 596 identify ATP-like compounds that could act as inhibitors of ROP18. Through this process, and 597 based on previous work demonstrating that expression of the appropriate ROP18 allele can 598 increase parasite growth in vitro, we examined the effects of these compounds on parasite 599
growth. This compound may not target ROP18, since there is no difference in sensitivity to this 600 compound in strains that express high levels of ROP18 and those that do not. Regardless, the 601 homology model of the ROP18 kinase domain, which was built based on similarity to two 602
Toxoplasma proteins with kinase folds (ROP2 and ROP8; (34)), served as a starting point for the 603 identification of compounds that may interact with parasite kinases. Future work will focus on 604 identifying the targets of this class of compounds. The importance of our study is that we were 605 able to identify benzodioxole-containing compounds that halt parasite growth in vitro. 606
The active compound F1792-0016 strongly inhibits parasite growth in vitro. This 607 compound contains both a quinoxaline group and a benzodioxole group, and by testing closely 608 related analogs (F1656-0035, F1792-0007 and F1792-0008; see Fig. 3 for structures) for their 609 activity against Toxoplasma, the benzodioxole moiety appears to be important for the inhibitory 610 activity of this compound. F1656-0035 has an identical structure except for the addition of a 611 methyl group on C-1 of the quinoxaline moiety, while F1792-0007 and F1792-0008 both have 612 altered forms of the benzodioxole. F1656-0035 inhibited parasite growth in vitro in a similar 613 fashion as F1792-0016 (albeit at reduced potency), while both F1792-0007 and F1792-0008 614 enhanced parasite growth in vitro. While the mechanism for the observed growth enhancement 615 by these two analogs is not known (i.e., whether the analogs are interacting with the same 616 target(s) as F1792-0016 or others), these restricted structure-activity studies suggest that the 617 benzodioxole moiety is important for the inhibitory activity of F1792-0016. 618
Benzodioxole-containing compounds have been implicated as inhibitors of eukaryotic 619 protein kinases, and their effects on the receptor tyrosine kinase EphB4 have been studied in 620 great detail (4-6). Benzodioxole-containing compounds were found to be highly effective at 621 inhibiting EphB4-activity in vitro, and co-crystals with EphB4 reveal that the benzodioxole 622 moiety interacts with the gatekeeper threonine residue in the kinase (6). When the benzodioxole 623 is substituted with other moieties, this dramatically reduces effectiveness against EphB4 (4). 624
The only exception to this was when the benzodioxole was substituted with an indazole, as this 625 compound retained activity against the kinase in vitro (4). In the Toxoplasma genome, most 626 predicted active kinases have bulky amino acids (e.g., Met, Leu, Ile) at the gatekeeper position, 627 and only a smaller subset of protein kinases from Toxoplasma have smaller residues like 628 threonine at this position (www.toxodb.org; unpublished data). The nature of the gatekeeper 629 residue, and in particular the presence of smaller amino acids at this position (such as threonine), 630 allows for alteration of the putative target for the kinase inhibitor and subsequent testing of the 631 parasites for resistance to the compound. In a bioinformatic survey of the Toxoplasma genome, 632 a gene coding for a cyclin-dependent protein kinase homologue (TGME49_019100) does have a 633 threonine residue at the gatekeeper position (www.toxodb.org). Based on the fact that transcript 634 levels of genes involved in transitions between different phases of the cell cycle are altered by 635 exposure to F1792-0016, and the fact that other benzodioxole-containing compounds interact 636 with the gatekeeper threonine in kinases like EphB4 (4-6), the Toxoplasma cyclin-dependent 637 kinase may be an excellent candidate for the target of F1729-0016. 638
The importance of the quinoxaline-containing moiety in F1792-0016 cannot be ruled out, 639 and other compounds with this core structure have been shown to have antimicrobial effects. In 640 particular, N-oxide-containing quinoxaline derivatives were shown to reduce the growth of 641
Mycobacterium tuberculosis both in vitro and in vivo (43, 50, 52, 53) , and the human malaria 642 parasite, Plasmodium falciparum (51). In the present study we have found that a quinoxaline-643 containing compound without 1,4 N-oxides is also effective against an apicomplexan parasite, in 644 this case Toxoplasma gondii. 645
Since T. gondii is an obligate intracellular parasite, determining whether effective 646 compounds are targeting the host cell, the parasite, or both can be difficult to address. In this 647 study we used an MTS assay and visual observation to address host cell cytotoxicity of the 648 compounds, and this led us to rule out compound F0920-5744. Based on these assays F1792-649 0016-exposed cells are healthy. However, the compounds could be altering parasite growth or 650 survival by altering certain key (and as yet unknown) signaling pathways within the host cell that 651 are crucial for Toxoplasma survival. When we treated uninfected host cells with F1792-0016 for 652 48 hours we found that very few host cell transcripts that were significantly altered in abundance, 653 except for a short list of genes involved in responding to stress and/or chemical insults (such as 654 P450 and TIPARP). Moreover, host cell treatment with an enhancer of parasite growth (F1792-655 0007) during the same experiment altered levels of 11 of the 12 transcripts altered by F1792-656 0016 treatment. This provides strong evidence that the inhibitory effects of F1792-0016 are due 657 to effects on the parasite, rather than the host cell. 
